Artificial IntelligenceBiotechConstructionEnergyFintechFunRobotsVirtual Reality

Biotech - All posts

This archives page shows all posts of this category. Go back to category guide: Biotech »

lab skin cells clock

Partial reprogramming shifted lab skin cells toward younger clocks

In a 2022 eLife study, researchers at the Babraham Institute and partner institutions used 13 days of maturation-phase transient reprogramming on middle-aged donors' skin fibroblasts and reported roughly thirty-year shifts on custom transcript and DNA methylation clocks, plus collagen-related signals and partial gains in a scratch-wound assay. Cells regained fibroblast identity in the dish; telomere lengthening was not seen on the methylation-based estimate used. FDA later cleared a separate company-sponsored phase 1 gene-therapy trial based on partial epigenetic reprogramming for optic neuropathies; starting that trial is not proof of anti-aging benefit in humans.

memory rejuvenation

Memory rejuvenation restored recall in mice

An EPFL Neuron study found that brief OSK gene activation in memory-trace neurons improved recall in aged and Alzheimer's-model mice. The result suggests some memory decline may reflect aging neurons rather than erased memories, but it does not show human memory restoration.

pill that cut LDL

A new cholesterol pill cut bad cholesterol by about 60% in a large trial

CORALreef Lipids is now peer-reviewed in the NEJM (4 February 2026): once-daily oral enlicitide decanoate on top of statins in most participants cut LDL cholesterol by about 56 percentage points versus placebo at 24 weeks, with similar short-term adverse-event rates in the trial. Cardiovascular outcome benefit for this oral drug is still unproven until CORALreef Outcomes reports.

Vision gains in early dry AMD stem cell transplant trial

An open-label phase 1/2a report in Cell Stem Cell covers the first six participants in the lowest-dose arm of a donor-derived RPE stem cell trial for geographic atrophy. Chart scores in the poorest-vision group rose on average at a 12-month visit, and the better-vision group showed a modest average gain at six months, but the cohort is too small and too early to treat as proof of efficacy or as standard care.